Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PDCD4
REST API REST API
Homo sapiens
PDCD4 is differentially expressed in 365 experiments: 163 organism parts: pancreas, salivary gland, ... (161 more);, 254 disease states: normal, glioblastoma, ... (252 more);, 118 cell types 510 cell lines 59 compound treatments and 79 other conditions.
Synonyms H731
Orthologs PDCD4 (Gallus gallus)   Pdcd4 (Mus musculus)   Pdcd4 (Rattus norvegicus)   pdcd4b (Danio rerio)   ENSCING00000013216 (Ciona intestinalis)   A4IFD1_BOVIN (Bos taurus)   CG10990 (Drosophila melanogaster)   pdcd4 (Xenopus laevis)   PDCD4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, negative regulation of transcription, DNA-dependent, protein binding, apoptosis, cytoplasm, negative regulation of JUN kinase activity, nucleus, binding, negative regulation of cell cycle, RNA binding, cell aging
InterPro Term Initiation_fac_eIF4g_MI
UniProt Accession Q53EL6, B5ME91, Q5VZS7
Search EB-eye ENSG00000150593
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823, E-GEOD-3529
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
SW480
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37
A549
2
E-GEOD-6013, E-GEOD-3202
BT-474
2
E-GEOD-5823, E-GEOD-3529
BT20
2
E-MTAB-37, E-MTAB-62
504 more value(s).


Cell type

studied in E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (54 experiments)

Factor Value U/D Experiments
CD4+ T cell
2
4
E-AFMX-5, E-GEOD-16190, E-MEXP-1600, E-TABM-145, E-GEOD-6740, ... (6 experiments)
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
not specified
2
E-GEOD-18811, E-GEOD-11755
CD8+ T cell
2
3
E-AFMX-5, E-TABM-145, E-GEOD-19069, E-GEOD-6740, E-MTAB-25 ... (5 experiments)
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-2248, E-MEXP-2426
112 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-MTAB-62, ... (77 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-GEOD-4412, E-MEXP-567 ... (5 experiments)
control
3
E-GEOD-8121, E-GEOD-21912, E-GEOD-20602
dermatomyositis
3
E-MTAB-62, E-GEOD-5370, E-GEOD-1551
gastric carcinoma
3
E-MTAB-37, E-GEOD-2685, E-GEOD-15460
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-231
astrocytoma
2
E-MTAB-37, E-GEOD-4290
248 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, ... (35 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
ethanol
2
E-MEXP-2241, E-GEOD-3113
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
FCCP
1
E-MEXP-2285
control - untreated
1
E-GEOD-7216
TGF-Beta1
1
E-MEXP-2645
53 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
74.51
1
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-GEOD-2666, E-GEOD-4667, E-MEXP-958, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-2152, E-GEOD-1045, E-GEOD-17476, E-TABM-868, E-GEOD-18005, ... (15 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-TABM-440, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-TABM-276, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-TABM-43, E-GEOD-1561, ... (6 experiments)

Processing time: 0.468 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM